fund momentum continu juli ytd
track multipl data point measur health biotech fund
environ accord bioworld comprehens data sourc
biotech fund includ public privat sourc increas
juli sequenti improv healthi june
latest data suggest fund promis molecul
biotech balanc sheet remain healthi bode well fundament
demand across cro univers caveat emphas fund
stem multipl sourc may fulli repres
data instanc larg pharmaceut compani repres key
sourc fund small mid-siz biotech compani inher
insul broader capit market activ ventur capit
public market fund
construct commentari
significantli improv biopharma environ small mid-
size biopharma compani grow faster top global
biopharmaceut compani key growth driver across cro
univers continu play increasingli import role
drug develop continuum innov engin less
total pipelin attribut top biopharma given biotech
increas ownership
unsurprisingli larger better fund decad ago includ
compani activ biopharma pipelin importantli
highlight biotech compani year cash bank
latest optim current biotech environ longer term
runway posit across broader cro univers
global pipelin
rais tp across cro univers light continu robust
biotech fund updat report bioworld conjunct
upbeat biotech commentari industri constitu rais target
price icon plc iqvia labcorp medpac hold health
scienc syneo health
respect risk call includ tighten biotech fund
cancel demand shift
next icrl host investor day septemb look
anoth updat biotech broader biopharma fund
environ well updat longer term outlook
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau pm univers toronto figur quarterli overal biotech fund includ public offer fund public
biotechnolog compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
figur monthli overal biotech fund includ public offer fund public biotechnolog
compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
biotechspublic/otherpubl biotechspublic/otherpubl growth charl martineau pm univers toronto figur public offer biotech compani includ ipo follow-on monthli
figur financ public biotechnolog compani monthli
includ loan bridg financ exercis warrant debt offer right offer standard privat placement
pipe financ institut offer regist stock
year-over-year growth growth year-over-year growth growth charl martineau pm univers toronto figur fund privat biotechnolog compani monthli
figur ipo fund healthcar compani monthli
note differ sourc bioworld data exclud siemen healthin billion ipo
growth year-over-year growth fund charl martineau pm univers toronto figur vc fund healthcar compani monthli
note differ sourc bioworld data
note data use multipl sourc may use differ threshold inclus thu data use indic broad trend
fund charl martineau pm univers toronto figur biopharma total
pipelin
figur biopharma total
pipelin
figur fda druv approv origin pharma
top biopharma biopharma biopharma charl martineau pm univers toronto figur estim biotech exposur cro
small/mid-s biotech mid-siz pharma larg pharma top biophama top biopharma smid biotech/oth academic/govern global may larg pharma larg biotech small/mid-s pharma emerg biotech top biophama top biopharma smid biopharma pro-forma follow inventiv breakdown state histor tradit clinic busi roughli larg pharma spec pharma/biotechiqvnot disclosednot disclosedno disclosur novella unit focus small biotech estim l-msd revenueprxlnot disclosednot disclosedno disclosur biopharm unit said grow rapidli focus exclus emerg biotech though like less exposur biotech otherscvdnot disclosednot disclosedno disclosur previous larg pharma biotech last disclos charl martineau pm univers toronto
price month
rais tp across cro univers
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price icon
plc risk call includ tighten biotech
fund demand shift cancellations/win
valuat metric
number share
 close
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
blue sky valuat iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky valuat iclr assum greater-
than-expect declin busi largest custom
consolid capit deploy misstep weaken demand
outsourc
 close
price month
rais tp across cro univers
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price iqvia
risk call includ tighten biotech fund
 demand shift new busi volatil
valuat metric
number share
 close
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
iqvia inc world largest contract research organ
cro lead healthcar inform technolog servic
blue sky scenario support bull
sotp scenario assum cost synergi im merger
exceed expect substanti cross sell cro
commerci servic exist new client greater new project
award due broader diversifi servic offer
pronounc strength spend fundament outsourc
grey sky scenario support bear
sotp scenario assum cost synergi take longer
expect captur integration-rel miscu includ
disrupt servic client capit deploy misstep
weaken demand outsourc relev
 close
labcorp america lh
rais tp across cro univers
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price labcorp
risk call includ tighten biotech fund
 demand shift potenti integr headwind govern
reimburs chang hospit lab competit
price month
valuat metric
number share
 close
labcorp america lh
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
labcorp provid diagnost test inform servic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
 close
rais tp across cro univers
price month
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price medpac
hold risk call includ tighten biotech
fund demand shift delays/cancel
valuat metric
number share
 close
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
oper
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
medpac full-servic therapeutically-focus contract
servic biopharmaceut medic devic industri
blue sky target assum signific
acceler organ sale growth healthi fund environ
increas profit success new servic offer
substanti new busi win continu strong outsourc
demand small/mid-s biotech custom
grey sky target assum deceler
sale growth declin profit weaken demand
small/mid-s biotech custom custom consolid
slowdown overal spend
 close
price month
rais tp across cro univers
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price
risk call includ tighten
biotech fund demand shift deal integr
valuat metric
number share
 close
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc contract research organ
servic biotechnolog pharmaceut industri
blue sky scenario assum meaning
acceler profit margin nt faster materi near term
revenu gener recent award addit strateg
partnership predic continu healthi industri dynam
deceler profit margin less revenu gener recent
award expect project cancel client loss custom
consolid slowdown outsourc demand
 close
rais tp across cro univers
price month
rais tp reiter outperform light continu robust biotech
fund data report bioworld conjunct upbeat biotech
commentari industri constitu rais target price syneo
risk call includ tighten biotech
fund demand shift cancel integr headwind
valuat metric
number share
 close
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global contract research organ cro oper
clinic drug develop commerci market
follow merger inventiv health second largest
cro largest contract commerci organ
blue sky scenario assum continu
industri lead growth sustain rel superior profit
larg pharma client sizabl project award lower
expect cancel continu strength spend
outsourc demand cross-sel opportun relat
merger inventiv health aug
grey sky scenario assum deceler
growth declin profit trajectori share loss weaken
demand small/mid-s biotech custom increas
cancel custom consolid headwind relat
inventiv integr slowdown spend
 close
compani mention price
labcorp america lh outperform tp
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
